Your donation will make a difference:
Cystic Fibrosis Trust
Forum

Trials Tracker

Welcome to the Trials Tracker, bringing together all the cystic fibrosis (CF) trials currently recruiting in the UK so that you can find clinical trials you can take part in both in your region and further afield. The Trials Tracker is a new resource that we’ll be developing over time based on your feedback. If you’ve used the Trials Tracker and want to share your opinion, please complete our online poll or get in touch at clinicaltrials@cysticfibrosis.org.uk.

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

11-15 of 54 results for all trials

Sort by:

Filter by

Trial status

Inclusion age

FEV1

Trial type

Location

Mutation

Therapeutic category

VX18-121-101 Safety and Efficacy of VX-121 combination therapy in CF

The purpose of this study is to evaluate the safety, tolerability and efficacy of VX-121 combination therapy in subjects with cystic fibrosis.

Phase II
  • Trial Reference Number

    113399

  • Age

    18+

  • Trial status

    Open to recruitment

  • Therapeutic category

    Restore CFTR Function

Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Adults With Cystic Fibrosis

The Study will assess the safety, tolerability, PK, and the effects of PTI-808 co-administered with PTI-801 with or without PTI-428 over a 28-day treatment period in CF subjects who are either homozygous for the F508del CFTR genotype or are heterozygous for the F508del CFTR genotype. Subjects will be randomized to receive treatment with PTI-808 co-administered with PTI-801 with or without PTI-428 versus matching placebo.

Read more Phase II
  • Trial Reference Number

    124674

  • Age

    18+

  • Trial status

    Open to recruitment

  • Therapeutic category

    Restore CFTR Function

A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis

This study will be conducted in 3 parts: a single ascending dose leading to a multiple ascending dose (MAD) in healthy volunteers, followed by a MAD in participants with cystic fibrosis. The study will enroll approximately 88 subjects. The study will consist of 4 single-dose randomized cohorts. Subjects enrolled will receive a single inhaled dose of the Study Drug (IONIS-ENaCRx or placebo) on Day 1.

Read more Phase I/II
  • Trial Reference Number

    122847

  • Age

    18+

  • Trial status

    Open to recruitment

  • Therapeutic category

    Mucociliary Clearance

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

This study will look at whether two drugs (called lumacaftor and ivacaftor) can help treat cystic fibrosis when taken together over a long period of time. It will also look at whether they are safe over this period. You can only take part in this study if you took part in a study called VX14-809-109, and if you meet certain criteria. These criteria will be checked by the study doctor and nurse at a screening visit. If you meet these criteria you will be treated with lumacaftor and ivacaftor together for approximately 96 weeks. A follow up visit will be held 28 days after the last dose of lumacaftor and ivacaftor. You will need to attend the clinic for 15 visits over the study duration and will undergo a range of tests. Participants who stopped taking the study drugs early in the VX14-809-109 study will be invited to take part in an observational study. They will not receive the study drug but will receive regular phone calls.

Read more Phase III
  • Trial Reference Number

    50600

  • Age

    0 - 12

  • Length of participation

    96 weeks

  • Trial status

    Open

  • Therapeutic category

    Restore CFTR Function

A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations

This study investigates the use of cysteamine in the treatment of adults with Cystic Fibrosis who are experiencing an exacerbation of CF-associated lung disease. There are six different potential dosing regimens, including one that is placebo.

Phase II
  • Trial Reference Number

    101870

  • Age

    18+

  • Length of participation

    3 weeks

  • Trial status

    Open to recruitment

  • Therapeutic category

    Mucociliary Clearance

11-15 of 54 results for all trials